News articles for Auxilium Pharmaceuticals, Inc.:
Wednesday, May 15, 2013
Friday, May 10, 2013
Monday, April 29, 2013
Auxilium Pharmaceuticals, Inc, Announces First Quarter 2013 Financial Results
CHESTERBROOK, Pa., April 29, 2013 /PRNewswire/ -- Auxilium Pharmaceuticals, Inc. (Nasdaq: AUXL), a specialty biopharmaceutical company, today announced financial results for the first quarter ending on March 31, 2013. The Company also highlighted important recent commercial, regulatory and clinical development progress in the first quarter of 2013.
(Logo: http://photos.prnewswire.com/prnh/20101202/MM10881LOGO )
For ...
read moreThursday, April 25, 2013
Auxilium Pharmaceuticals to Announce First Quarter 2013 Results and Conduct Conference Call on Monday, April 29, 2013
CHESTERBROOK, Pa., April 25, 2013 /PRNewswire/ -- Auxilium Pharmaceuticals, Inc. (NASDAQ: AUXL), a specialty biopharmaceutical company, will release results for the first quarter 2013 on Monday, April 29, 2013 before the opening of the U.S. financial markets. The Company will also conduct a conference call that day ...
read more Monday, March 25, 2013
Monday, March 4, 2013
Tuesday, February 26, 2013
Tuesday, February 12, 2013
Auxilium Pharmaceuticals, Inc. to Present at the Leerink Swann Global Healthcare Conference
CHESTERBROOK, Pa., Feb. 12, 2013 /PRNewswire/ -- Auxilium Pharmaceuticals, Inc. (Nasdaq: AUXL) today announced that executive management will participate in the Leerink Swann Global Healthcare Conference to be held February 13-14, 2013 at the Waldorf Astoria Hotel in New York City. Mr. Adrian Adams, Chief Executive ...
read moreAuxilium Pharmaceuticals to Announce Fourth Quarter and Full Year 2012 Results and Conduct Conference Call on Tuesday, February 26, 2013
CHESTERBROOK, Pa., Feb. 12, 2013 /PRNewswire/ -- Auxilium Pharmaceuticals, Inc. (NASDAQ: AUXL), a specialty biopharmaceutical company, will release results for the fourth quarter and full year 2012 on Tuesday, February 26, 2013 before the opening of the U.S. financial markets. The Company will also conduct a conference ...
read more Friday, February 1, 2013
Wednesday, January 30, 2013
Monday, January 28, 2013
Auxilium Pharmaceuticals, Inc. and Xstelos Holdings, Inc. File Lawsuit Against Upsher-Smith Laboratories, Inc. for Infringement of Testim® Patents
MALVERN, Pa. and NEW YORK, Jan. 28, 2013 /PRNewswire/ -- Auxilium Pharmaceuticals, Inc. (NASDAQ: AUXL) ("Auxilium") and Xstelos Holdings, Inc. (OTCQB: XTLS) ("Xstelos") announced today that they filed a lawsuit against Upsher-Smith Laboratories, Inc. ("USL") for infringement of ten U.S. patents covering Testim, 1% testosterone gel, ...
read more Friday, January 25, 2013
Wednesday, January 23, 2013
Monday, January 7, 2013
Auxilium Pharmaceuticals, Inc. Announces Expansion of Its Exclusive License for XIAFLEX® (CCH) to Include the Potential Treatment of Cellulite as an Additional Indication
MALVERN, Pa., Jan. 7, 2013 /PRNewswire/ -- Auxilium Pharmaceuticals, Inc. (NASDAQ: AUXL) ("Auxilium"), a specialty biopharmaceutical company, today announced that it has exercised its exclusive option under the Second Amended and Restated Development and License Agreement ("CCH License Agreement"), dated as of August 31, 2011, with BioSpecifics ...
read more Thursday, January 3, 2013
Auxilium Pharmaceuticals, Inc. and Xstelos Holdings, Inc. Receive 505(b)(2) Paragraph IV Certification Notice from Upsher-Smith Laboratories, Inc. for Testim®
MALVERN, Pa. and NEW YORK, Jan. 3, 2013 /PRNewswire/ -- Auxilium Pharmaceuticals, Inc. (NASDAQ: AUXL) ("Auxilium") and Xstelos Holdings, Inc. (OTCQB: XTLS) ("Xstelos") today announced that they have received a notice from Upsher-Smith Laboratories, Inc. ("USL") that advises them of USL's filing of a 505(b)(2) New Drug ...
read moreThursday, December 27, 2012
Thursday, December 13, 2012